Company intelligence / Profile preview

Entegrion

Durham, North Carolina, United Statesentegrion.com ↗

Ownership: Private
Employees: ~13
Development stage: Commercial

Overview

Entegrion’s main product, VCM™, is a point-of-care viscoelastic coagulation monitoring device that provides rapid assessment of hemostasis without the need for chemistry. The company has received significant funding from the U.S. Department of Defense and its technologies are designed for both civilian and military use. The VCM™ system has achieved CE Mark regulatory clearance in Europe. Clinical results have not been detailed in public sources but regulatory progress suggests successful validation.

Therapeutic areas: Hematology
Modalities: DeviceBiologic (potentially, based on pipeline description)
Industry: Physiological Monitoring

Drug pipeline

1 asset

VCM

Commercial

Indications: Blood coagulation monitoring

Partnerships

U.S. Department of Defense (major funding partner)

Beyond the preview

Go deeper on Entegrion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Entegrion.

Explore the full profile